(3) Collection of PBSC’s from Normal Donors. 
Patients receiving syngeneic marrow transplants are an ideal group to evaluate 
the effects of growth factors. Identical twins have recently been included in 
studies of post-transplant growth factors. PBSC can be infused into an identical 
twin recipient fresh without concern about graft-vers us-host disease. The twin 
donor is available for backup marrow if engraftment does not occur. Four 
identical twins have received syngeneic marrow followed by the post-transplant 
infusion of buffy-coat cells collected after the administration of G-CSF to the 
normal donor. The design of this study was to optimize granulocyte collections 
and not PBSC’s. They were treated on a dose escalation study of G-CSF designed 
to investigate optimal granulocyte collection data. Donors received G-CSF 
beginning on day 0 after marrow harvest. The dose was 300 /zg. Buffy coat cells 
were collected and infused on post-transplant days. 
Table ID summarizes engraftment characteristics of the identical twins receiving 
marrow and G-CSF stimulated buffy coat. 
Table m 
Recipients of Syngeneic Marrow and G-CSF Stimulated Bufly Coat 
. Day? 
Day 
Day 
Day 
Day 
spent 
to 
to 
to 
to 
No. Trans. 
ANC 
ANC 
ANC 
ANC 
Pits 
of of 
UPN 
Dx 
Regimen 
<100 
>100 
>500 
>1000 
>20 
Pits RBC 
6536 
CML 
Bu/Cy/TBI, BM+BC 
0 
- 
12 
13 
17 
90 
10 
6545 
BrCa 
Bu/Cy, BM+BC 
0 
- 
14 
15 
20 
76 
2 
6630 
AML 
Bu/Cy/TBI, BM+BC 
1 
7 
10 
12 
18 
26 
0 
6785 
NHL 
VP16/Cy/TBI, BM+BC 
0 
- 
6 
8 
- 
0 
0 
6672 
CML 
Bu/Cy/TBI, Bm + Be 
4 
9 
10 
13 
18 
54 
8 
Recipients of Syngeneic Marrow and Post-transplant Growth Factors 
Two patients have received syngeneic marrow transplants and post-transplant recombinant G or GM- 
CSF. The engraftment data on these 2 patients is shown in Table IV. 
Table IV 
Days 
Day 
Day 
Day 
Day 
spent 
to 
to 
to 
to 
No. Trans. 
ANC 
aNC 
ANC 
ANC 
Pits 
of of 
UPN 
Dx 
Regimen 
<100 
>100 
>500 
>1000 
>20,000 
Pits RBCs 
6591 
CML 
Bu / Cy/TBI + G-CSF 
0 
• 
9 
12 
21 
86 
7 
3854 
NHL 
TBI/VP-16/Cy + GM-CSF 
1 
8 
14 
21 
14 
38 
Recombinant DNA Research, Volume 16 
[363] 
